Tudor Investment Corp ET AL Takes $6.06 Million Position in LeMaitre Vascular, Inc. $LMAT

Tudor Investment Corp ET AL bought a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 3rd quarter, HoldingsChannel reports. The institutional investor bought 69,202 shares of the medical instruments supplier’s stock, valued at approximately $6,056,000.

Several other institutional investors also recently modified their holdings of LMAT. Royal Bank of Canada grew its holdings in shares of LeMaitre Vascular by 1.5% in the first quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock valued at $9,579,000 after acquiring an additional 1,735 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of LeMaitre Vascular by 36.4% in the first quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock valued at $2,339,000 after acquiring an additional 7,445 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in LeMaitre Vascular by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after purchasing an additional 539 shares during the last quarter. Millennium Management LLC lifted its stake in LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after purchasing an additional 115,141 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after purchasing an additional 55,804 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Wells Fargo & Company upped their price objective on LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research note on Thursday, February 26th. Citizens Jmp upped their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. Roth Mkm reiterated a “buy” rating and issued a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Finally, Freedom Capital upgraded LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $105.80.

Insiders Place Their Bets

In other LeMaitre Vascular news, insider Trent G. Kamke sold 1,044 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $110.29, for a total transaction of $115,142.76. Following the sale, the insider owned 6,677 shares in the company, valued at $736,406.33. This represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO George W. Lemaitre sold 55,930 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $107.81, for a total value of $6,029,813.30. Following the sale, the chief executive officer owned 1,476,500 shares in the company, valued at approximately $159,181,465. This represents a 3.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 215,438 shares of company stock worth $23,062,911 over the last 90 days. Corporate insiders own 9.50% of the company’s stock.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $110.33 on Wednesday. The company has a market cap of $2.51 billion, a price-to-earnings ratio of 43.96, a PEG ratio of 3.12 and a beta of 0.67. The business’s 50 day simple moving average is $100.13 and its 200 day simple moving average is $90.88. LeMaitre Vascular, Inc. has a 12 month low of $77.01 and a 12 month high of $115.33. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.01. The firm had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The business’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th were given a dividend of $0.25 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 39.84%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.